GO:0019254 carnitine metabolic process, CoA-linked

Carnitine metabolic process, CoA-linked (GO:0019254) is a biological process that encompasses the chemical reactions and pathways involving carnitine, where metabolism is linked to coenzyme A (CoA). This term captures the essential role of carnitine in cellular energy metabolism, particularly in the transport of long-chain fatty acids into mitochondria for beta-oxidation. The CoA-linked aspect highlights the interdependence of carnitine metabolism with acyl-CoA pools, which are central to fatty acid oxidation and energy production. Researchers study GO:0019254 because disruptions in carnitine metabolism can lead to severe metabolic disorders, including defects in oxidative phosphorylation. Understanding the genes and enzymes involved in this process provides insights into mitochondrial function and the pathophysiology of inherited metabolic diseases. Moreover, carnitine metabolism is relevant to broader areas such as cancer metabolism, neurodegeneration, and metabolic syndrome, making it a subject of ongoing investigation. This article provides a comprehensive overview of GO:0019254, including its definition, key genes, regulatory mechanisms, disease associations, and research methodologies. By integrating authoritative QuickGO data and published literature, we aim to support researchers in exploring this critical metabolic pathway.

GO:0019254, carnitine metabolic process, CoA-linked, is defined as the chemical reactions and pathways involving carnitine, where metabolism is linked to CoA. This includes the biosynthesis of carnitine from protein-derived trimethyllysine, the transport of carnitine and its derivatives across membranes, and the reversible conversion of carnitine to acylcarnitines via carnitine acyltransferases. The CoA-linked designation indicates that these reactions are directly coupled to the metabolism of acyl-CoA molecules, which are key intermediates in fatty acid oxidation and other metabolic pathways.

GO:0019254 is fundamentally important because carnitine metabolism is indispensable for mitochondrial fatty acid oxidation, a process that generates energy in the form of ATP. Defects in this pathway can lead to a range of clinical manifestations, including cardiomyopathy, skeletal myopathy, hypoglycemia, and sudden death, as seen in inherited fatty acid oxidation disorders. Furthermore, carnitine metabolism intersects with other critical cellular processes, such as the regulation of acyl-CoA pools, which influence gene expression, signaling, and membrane composition. Understanding GO:0019254 is therefore essential for diagnosing and treating metabolic diseases and for advancing research in mitochondrial biology.

The following genes encode proteins that are directly involved in carnitine metabolic process, CoA-linked, as supported by published literature.

Carnitine metabolic process, CoA-linked is regulated by a network of transcription factors, signaling pathways, and metabolic feedback mechanisms. The peroxisome proliferator-activated receptor alpha (PPARA) and its coactivator PGC-1alpha (PPARGC1A) are master regulators of genes involved in fatty acid oxidation, including CPT1A, CPT1B, and ACADM. Malonyl-CoA acts as a potent inhibitor of CPT1, linking carnitine metabolism to lipogenesis and energy status. Additionally, AMP-activated protein kinase (AMPK) senses cellular energy stress and can phosphorylate and inhibit acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and thereby activating CPT1. Hormonal signals, such as insulin and glucagon, also modulate carnitine metabolism through effects on gene expression and enzyme activity.

Defects in genes involved in carnitine metabolic process, CoA-linked, such as CPT2, SLC25A20, and ACADVL, cause inherited fatty acid oxidation disorders. These conditions often present in infancy or early childhood with hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and Reye-like syndrome. Biochemical investigations in skeletal muscle can reveal defects in oxidative phosphorylation, as reported by Scholte et al. (1987). Early diagnosis and dietary management, including carnitine supplementation, are critical for improving outcomes.

Primary carnitine deficiency is caused by mutations in SLC22A5, which encodes the OCTN2 transporter, leading to impaired cellular carnitine uptake. This disorder is characterized by low plasma and tissue carnitine levels, resulting in cardiomyopathy, muscle weakness, and hypoglycemia. Secondary carnitine deficiency can arise from other metabolic disorders or medications, further highlighting the importance of carnitine metabolism in human health.

Carnitine metabolism is intimately linked to mitochondrial oxidative phosphorylation, and defects in this process can manifest as mitochondrial myopathies. Scholte et al. (1987) described biochemical investigations in skeletal muscle that revealed defects in oxidative phosphorylation, emphasizing the role of carnitine metabolism in mitochondrial energy production. Such defects can lead to exercise intolerance, muscle weakness, and lactic acidosis.

Quantification of carnitine and acylcarnitines in biological samples is typically performed using tandem mass spectrometry (MS/MS) or high-performance liquid chromatography (HPLC). These methods allow for the detection of specific acylcarnitine species, which serve as biomarkers for fatty acid oxidation disorders. Enzyme activity assays for CPT1, CPT2, and other carnitine metabolism enzymes can be conducted in tissue homogenates or cultured cells.

Next-generation sequencing, including whole-exome and whole-genome sequencing, is used to identify mutations in genes associated with carnitine metabolism. RNA-seq can reveal changes in gene expression in response to metabolic perturbations or genetic modifications. CRISPR-based gene editing enables the creation of isogenic cell lines with specific mutations to study gene function.

Seahorse extracellular flux analysis measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to assess mitochondrial respiration and glycolysis. Fluorescent probes such as TMRM or JC-1 can be used to measure mitochondrial membrane potential. These assays help evaluate the impact of carnitine metabolism defects on oxidative phosphorylation.

Mass spectrometry-based proteomics can quantify the abundance of enzymes involved in carnitine metabolism. Metabolomics profiling provides a comprehensive view of metabolic changes, including carnitine and acylcarnitine levels, in response to genetic or environmental perturbations. These approaches are valuable for identifying biomarkers and understanding pathway dynamics.

Researchers studying carnitine metabolic process, CoA-linked-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with metabolic changes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic modifications, from knockout to knock-in, in a variety of cell models. By leveraging our expertise, you can accelerate your research on carnitine metabolism and its role in health and disease.

GO:0019254, carnitine metabolic process, CoA-linked, is a fundamental biological process that bridges carnitine homeostasis with acyl-CoA metabolism and mitochondrial energy production. Its dysregulation is implicated in a spectrum of inherited metabolic disorders, making it a critical area of research. By employing advanced genetic and biochemical tools, researchers can uncover novel insights into the mechanisms and therapeutic opportunities associated with this pathway. EDITGENE is committed to supporting this research through its comprehensive CRISPR-based services, enabling the creation of precise cell models to study carnitine metabolism genes and their roles in health and disease.